EML4-ALK in NSCLC: The OSU Experience.

  title={EML4-ALK in NSCLC: The OSU Experience.},
  author={Erin M Bertino and Weiqiang J Zhao and Miguel A. Villalona-Calero and Nagla Abdel Karim and Konstantin Shilo and Gregory Alan Otterson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={29 15_suppl},
e18014 Background: EML4-ALK gene translocation is a novel carcinogenic change described in NSCLC in 2007. Prior studies report this translocation in 1-11% of screened patients (pts) and an association with never/light smoking, male sex, absence of EGFR or KRAS mutations, and adenocarcinoma histology. Compared to other NSCLC pts, ALK positive pts have similar responses to platinum chemotherapy, resistance to erlotinib, and no difference in OS. 82 ALK positive NSCLC pts were treated on a phase I… CONTINUE READING